FDA approves Vertex’s acute pain treatment Journavx
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with acute pain. The FDA has approved the non-opioid, highly selective NaV1.8 pain signal inhibitor for administration twice daily.
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
The company has heavily advertised AI features since the latest iPhones were released in September. Revenue rose 10% from a year ago to $9.5 billion. The shift occurs after many brands cut their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback